Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now

CMS’s Contract-Year 2026 Final Rule (CMS-4208-F) and related guidance turn Inflation Reduction Act concepts into operational reality for Part B drugs. Add the forthcoming WISeR prior-auth pilot and you have the most radical overhaul of Medicare pharmacy policy since 2003.

Snapshot of 2026 Changes

  • Price Negotiation: The first 15 high-spend Part B biologics enter negotiation; ceiling prices publish Sept 1 2026.

  • Prescription Payment Plan: Part D out-of-pocket cap set at $2,100 and spread over 12 installments.

  • Prior-Authorization Expansion: Traditional Medicare adds AI-enabled PA for 17 services in NJ, OH, OK, TX, AZ, WA under WISeR.

  • Site-Neutral Study: EO-driven analysis may tie Part B payment to physician-office rates by 2028.

Financial Impact on Infusion Centers

Health-economics models estimate negotiated prices could trim Part B reimbursement 15 – 25 % for selected drugs, with commercial payers likely to follow within two years. Margin compression will be most acute for buy-and-bill oncology practices.

Four “No-Regrets” Moves for 2025

1. Map Exposure to Negotiated Molecules

Cross-walk your top-20 Part B drugs against CMS’s negotiation-eligibility list; flag anything >10 % of drug revenue.

2. Rebalance Charge Capture

Align HCPCS unit definitions and wastage billing; CMS auditors identified $160 million in wastage-related overpayments in 2024.

3. Strengthen PA Automation

WISeR will require machine-readable documentation. Early adopters using AI-assisted PA have reduced denial-overturn time by ~40 %.

4. Scenario-Plan Site-Neutral Cuts

A 12-chair HOPD moving 30 % of infusions off-campus avoided a projected 9 % revenue loss under simulated site-neutral rates.

Conclusion

Medicare’s 2026 reforms will squeeze drug margins while tightening administrative rules. Providers that pre-model price cuts, embrace biosimilars, and automate prior auth will turn disruption into a competitive edge—and ensure patients keep receiving the treatments they need

> Start today <

Let us take care of the MESS(y) data

Click below to get access to our product and explore how Trellis can help you and your organization unlock new insights!

Book demo

2025 Trellis. All rights reserved.

2025 Trellis. All rights reserved.